Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

26.72 -1.58 (-5.58%)
Streaming Delayed Price Updated: 12:43 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Beam Therapeutics Inc

< Previous 1 2 Next >
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Upcoming September Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States 
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives. 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
From Pfizer Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.